Expiration date: 04/2026

Composition and form of release:

Solution for injection 2 ml

active substance:

the human placenta extract 112 mg

excipients: water for injections pH Adjuster (sodium hydroxide or hydrochloric acid)

in vials of dark glass, hydrolytic class 2, with a spot of white color, indicating the place of the breaking of the ampoule, 2 ml, in cartons with dividers from cardboard at 10 or 50 ampoules.

Description of the dosage form:

Transparent liquid from light yellow to brown in color with a characteristic smell.

Description of the pharmacological action:

Laennek exhibits immunomodulatory properties due to the ability to stimulate humoral immunity and increase the functional activity of phagocytes and natural killers increases the bactericidal activity of peripheral blood leukocytes, manifested in their ability to destroy the captured pathogen. Cytokines, which are part of the drug, activate the metabolic and supervisory functions of skin cells.

Biologically active substances contained in the hydrolysate stimulate the regeneration (proliferation) of hepatocytes, exhibit detoxifying properties, reduce the deposition of lipids and cholesterol in liver cells, increase the activity of tissue respiration, activate the metabolism in the liver, reduce the intensity of the development of connective tissue in the liver.

Indications:

in the complex therapy of the following diseases: chronic recurrent herpes, atopic dermatitis of moderate and severe course (including complicated)

in the form of monotherapy for chronic liver diseases: steatohepatitis (alcoholic, metabolic and mixed etiology).

Contraindications:

• hypersensitivity
• children's age
• pregnancy
• the lactation period.

Side effect:

They are noted in 3.7% of patients.

Clinically significant adverse reactions

Allergic reactions, including anaphylactic shock, are possible.

Other undesirable phenomena

Soreness at the injection site — 2, 56%, allergic reactions (redness, itching of the skin) - 0, 37%, numbness at the injection site — 0, 37%, gynecomastia (a causal relationship with the administration of the drug has not been established) - 0, 37%.

Drug interaction:

When Laennec is mixed with other drugs that are strong bases (pH<, 8, 5= "" p="">,

There is no information about any other clinically significant interactions of Laennek to date.

Method of administration and dosage:

Chronic recurrent herpes and atopic dermatitis

Intravenous drip: 10 ml (540 mg of placenta hydrolysate) of the drug (5 ampoules) is dissolved in 250-500 ml of 5% dextrose solution or saline solution and injected through the ulnar vein for 1, 5-2 hours. Injections are carried out 3 times a week with an interval of 2 days. The course of treatment is 10 injections.

Chronic liver diseases: steatohepatitis (alcoholic, metabolic and mixed etiology)

I / m: 2 ml per day (112 mg of placenta hydrolysate). Depending on the severity of the disease, the frequency of injections can be increased up to 2-3 times (up to 6 ml) per day.

Intravenous drip: 10 ml (560 mg of placenta hydrolysate) of the drug (5 ampoules) is dissolved in 250-500 ml of 5% dextrose solution or saline solution and injected through the ulnar vein for 1, 5-2 hours. Injections are carried out daily. The course of treatment is 2-3 weeks.

Overdose:

Currently, no cases of overdose of Laennek have been reported.

Safety precautions:

Use of the drug in children

Studies on the safety of the use of Laennec in premature infants, newborns, infants and minors have not been conducted. Use in children is not recommended.

Use of the drug in the elderly

According to the currently available data, old age is not a contraindication for the appointment of Laennek. However, since the physiological functions of the elderly are deteriorating, the use of the drug should be carried out under careful monitoring.